June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Intraocular lens biocompatibility: a novel, objective approach
Author Affiliations & Notes
  • Christina Mastromonaco
    MUHC McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Matthew Balazsi
    Engineering , Medical Parachute, Montreal, Quebec, Canada
  • Evangelina Esposito
    MUHC McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Jacqueline Coblentz
    MUHC McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Aya Siblini
    MUHC McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Jade Lasiste
    MUHC McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Miguel N Burnier
    MUHC McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Christina Mastromonaco, None; Matthew Balazsi, Medical Parachute (P), Medical Parachute (I); Evangelina Esposito, None; Jacqueline Coblentz, None; Aya Siblini, None; Jade Lasiste, None; Miguel Burnier, Alcon (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3192. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christina Mastromonaco, Matthew Balazsi, Evangelina Esposito, Jacqueline Coblentz, Aya Siblini, Jade Lasiste, Miguel N Burnier; Intraocular lens biocompatibility: a novel, objective approach. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3192.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Understanding factors that contribute to posterior capsular opacification (PCO) development is a significant public concern as treatment can lead to complications. In order to prevent PCO, a better understanding of intraocular lens (IOL) characteristics, including design and material, and patient interaction is required. Herein, we performed a retrospective multivariable analysis to determine which factors (IOL and patient based) were least likely to result in PCO.

Methods : 180 post-mortem eyes with implanted IOLs were collected from the Minnesota Eye Bank, along with clinical history, including date of cataract surgery and IOL model number. The capsular bag (CB) with the IOL implant was removed from all eyes to obtain digital images. PCO outcome was quantified on CB images using an objective, automated custom image analyzer (Medical Parachute Automated Detector Opacification Software). The software measured intensity and area of the opacification within the IOL optic edge, intra-optic edge (IOE=intensity/area), and in Soemmering’s ring (SR=intensity/area). Epidemiologic analysis assessed which IOL characteristics and patient-related factors correlated with PCO. IOL factors included material, edge design, lens filter, company, IOL model, decentration and time from cataract surgery to death. Patient factors included sex, age and diabetes, among others.

Results : Multivariate analyses showed non-diabetic patients had less PCO (P=0.05). Individuals 50-80 years old compared to 80+ had lower SR PCO (P=0.04). Non-blue light filter IOLs had lower SR and IOE PCO compared to filter IOLs (P=0.03, 0.001). Square and frosted optic edge design had lower SR and IOE PCO rates compared to OptiEdge and round optic edge design (P=0.002, 0.02). The IOL model that had the least PCO was the ZA9003 model, but this was only significant for SR and not IOE PCO (P=0.04). Adjusting for patient-factors, IOL lens model was no longer a confounding factor for PCO. Patients with an IOL implanted for <7 years had lower SR PCO, whereas lower IOE PCO was only seen in implants <4 years old (P=0.0001, 0.04).

Conclusions : In order to generate a lens that does not develop PCO, it is critical to understand the IOL- and patient-related factors that lead to PCO development. Based on our data, the most susceptible patients are elderly and diabetic, and it may be preferable to implant a square and frosted edge lens without blue-light filtering in this cohort.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.